Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Over the next 10 years a significant number of key oncology products, some with blockbuster status, will lose patent protection, thus exposing billions of dollars to generic erosion. While obviously a major threat to the key pharmaceutical players and sales of their branded products, this presents significant opportunities to potential generic manufacturers.


Scope

  • Overview of the current generic cancer market, including profiles of key products and events impacting each during 2004 to 2014
  • Assessment of current and future opportunities and threats in the generic cancer market across the seven major pharmaceutical markets
  • Individual country, EU5 and seven-market sales forecasts from 2004 to 2014 for branded products and their generic counterparts
  • Detailed discussion of key strategic issues in the generic cancer market, plus three commercial impact and lifecycle management case studies


    • Report Highlights
    The generic cancer market was worth $1.3 billion in 2004, and is set to grow at a CAGR of 24.3% to reach $10.9 billion by 2014. All classes of drugs are set to enjoy significant growth, although in some cases this is highly dependent on finalization and implementation of an explicit regulatory framework for the approval of biogenerics.

    The cytotoxics and antihormonal therapy classes already suffer a high level of genericization, therefore further growth will arise via the patent expiration of existing newer products, some of which currently achieve, or are forecast to achieve, blockbuster sales of over $1 billion a year by 2014.

    The targeted therapies and supportive care products offer perhaps the greatest opportunities for generic players, given their potential for blockbuster sales and key roles in cancer management. However, potential players in these markets must be prepared to wait for the relevant biogeneric legislation to be passed.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key generic cancer therapies
  • Assess the impact of patent expiries on key brand name products and identify the opportunities and risks for generic drugs in the seven major markets
  • Adopt knowledge to drive strategic planning for generic products and optimize market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: generic patent generic market expiry oncology cancer expiration proleukin generics sales

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.